Literature DB >> 28123554

Recognition of tumor antigens in 4T1 cells by natural IgM from three strains of mice with different susceptibilities to spontaneous breast cancer.

Mariana Díaz-Zaragoza1, Ricardo Hernández-Ávila1, Pedro Ostoa-Saloma1.   

Abstract

The issue of antibody responses to tumors is potentially important to cancer immunologists. Early detection of cancer represents one of the most promising approaches to reduce the growing cancer burden. Natural immunoglobulin (Ig)M antibodies have been associated with the recognition and elimination of cancerous and precancerous cells. Using natural IgM antibodies, the present study identified a set of antigens in healthy mice from three different strains and examined whether the global patterns of antibodies are able to discriminate between a condition of more or less susceptibility to breast cancer. The current study performed two-dimensional (2D) immunoblotting to detect antigens from 4T1 cells using natural IgM from serum of healthy female mice from three different strains. The t-test was used to analyze the total number of spots. There were no significant differences in the numbers of antigens recognized in each strain. However, differences in patterns were observed on 2D immunoblots among the three strains. The reactivity patterns of natural IgM antibodies to particular antigens exhibited non-random clustering, which discriminated between strains with different susceptibilities to spontaneous breast cancer. The results demonstrated that the patterns of reactivity to defined subsets of antigens are able to provide information regarding differential diagnosis associated with breast cancer sensitivity. Therefore, it may be concluded that it is possible to segregate the IgM humoral immune response toward cancer antigens according to the genetic background of individuals. In addition, it is possible to identify the recognized antigens that allow grouping or discriminate between the different IgM antibodies expressed. The possible association between a particular antigen and cancer susceptibility requires further study, but the methodology exposed in the present study may identify potential candidates for this possible association.

Entities:  

Keywords:  4T1 cells; breast cancer; immunoglobulin M; mice strains; two-dimensional immunoblot

Year:  2016        PMID: 28123554      PMCID: PMC5244975          DOI: 10.3892/ol.2016.5427

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  15 in total

1.  Immune response as a biomarker for cancer detection and a lot more.

Authors:  Olivera J Finn
Journal:  N Engl J Med       Date:  2005-09-22       Impact factor: 91.245

Review 2.  The sentinel within: exploiting the immune system for cancer biomarkers.

Authors:  Karen S Anderson; Joshua LaBaer
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

3.  Global analysis of antibody repertoires. II. Evidence for specificity, self-selection and the immunological "homunculus" of antibodies in normal serum.

Authors:  A Nobrega; M Haury; A Grandien; E Malanchère; A Sundblad; A Coutinho
Journal:  Eur J Immunol       Date:  1993-11       Impact factor: 5.532

4.  Comparison patterns of 4 T1 antigens recognized by humoral immune response mediated by IgG and IgM antibodies in female and male mice with breast cancer using 2D-immnunoblots.

Authors:  Mariana Díaz-Zaragoza; Ricardo Hernández-Ávila; Tzipe Govezensky; Luis Mendoza; Dulce María Meneses-Ruíz; Pedro Ostoa-Saloma
Journal:  Immunobiology       Date:  2015-05-18       Impact factor: 3.144

Review 5.  Use of autoantibodies in breast cancer screening and diagnosis.

Authors:  Sarah J Storr; Jayeta Chakrabarti; Anthony Barnes; Andrea Murray; Caroline J Chapman; John F R Robertson
Journal:  Expert Rev Anticancer Ther       Date:  2006-08       Impact factor: 4.512

Review 6.  Autoantibodies to tumor-associated antigens: reporters from the immune system.

Authors:  Eng M Tan; Jianying Zhang
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

7.  Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.

Authors:  Caroline Desmetz; Caroline Bascoul-Mollevi; Philippe Rochaix; Pierre-Jean Lamy; Andrew Kramar; Philippe Rouanet; Thierry Maudelonde; Alain Mangé; Jerome Solassol
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

Review 8.  Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer.

Authors:  Hailing Lu; Vivian Goodell; Mary L Disis
Journal:  J Proteome Res       Date:  2008-02-27       Impact factor: 4.466

Review 9.  Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review).

Authors:  Mariana Díaz-Zaragoza; Ricardo Hernández-Ávila; Rubí Viedma-Rodríguez; Diego Arenas-Aranda; Pedro Ostoa-Saloma
Journal:  Oncol Rep       Date:  2015-06-30       Impact factor: 3.906

10.  2D immunoblots show differential response of mouse IgG and IgM antibodies to antigens of mammary carcinoma 4 T1 cells.

Authors:  Mariana Díaz-Zaragoza; Ricardo Hernández; Pedro Ostoa-Saloma
Journal:  Cancer Cell Int       Date:  2014-01-28       Impact factor: 5.722

View more
  3 in total

1.  Immune Surveillance by Natural IgM Is Required for Early Neoantigen Recognition and Initiation of Adaptive Immunity.

Authors:  Shaikh M Atif; Sophie L Gibbings; Elizabeth F Redente; Faye A Camp; Raul M Torres; Ross M Kedl; Peter M Henson; Claudia V Jakubzick
Journal:  Am J Respir Cell Mol Biol       Date:  2018-11       Impact factor: 6.914

Review 2.  Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.

Authors:  Camille Jacqueline; Olivera J Finn
Journal:  Semin Immunol       Date:  2020-04-06       Impact factor: 11.130

Review 3.  Drivers and regulators of humoral innate immune responses to infection and cancer.

Authors:  Deepak Kumar; Yeni Romero; Kaitlynn N Schuck; Haley Smalley; Bibek Subedi; Sherry D Fleming
Journal:  Mol Immunol       Date:  2020-03-18       Impact factor: 4.407

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.